- Home
- DHY vs HUMA Comparison
DHY vs HUMA Comparison
Compare DHY & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- HUMA
- Stock Information
- Founded
- DHY 1998
- HUMA 2004
- Country
- DHY United States
- HUMA United States
- Employees
- DHY N/A
- HUMA N/A
- Industry
- DHY Finance/Investors Services
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- HUMA Health Care
- Exchange
- DHY Nasdaq
- HUMA Nasdaq
- Market Cap
- DHY 220.7M
- HUMA 250.2M
- IPO Year
- DHY N/A
- HUMA N/A
- Fundamental
- Price
- DHY $2.09
- HUMA $1.43
- Analyst Decision
- DHY
- HUMA Strong Buy
- Analyst Count
- DHY 0
- HUMA 8
- Target Price
- DHY N/A
- HUMA $10.88
- AVG Volume (30 Days)
- DHY 569.1K
- HUMA 5.6M
- Earning Date
- DHY 01-01-0001
- HUMA 08-11-2025
- Dividend Yield
- DHY 9.10%
- HUMA N/A
- EPS Growth
- DHY N/A
- HUMA N/A
- EPS
- DHY N/A
- HUMA N/A
- Revenue
- DHY N/A
- HUMA $818,000.00
- Revenue This Year
- DHY N/A
- HUMA N/A
- Revenue Next Year
- DHY N/A
- HUMA $949.92
- P/E Ratio
- DHY N/A
- HUMA N/A
- Revenue Growth
- DHY N/A
- HUMA N/A
- 52 Week Low
- DHY $1.77
- HUMA $1.15
- 52 Week High
- DHY $2.08
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- DHY 43.42
- HUMA 32.47
- Support Level
- DHY $2.07
- HUMA $1.43
- Resistance Level
- DHY $2.11
- HUMA $1.67
- Average True Range (ATR)
- DHY 0.02
- HUMA 0.12
- MACD
- DHY 0.00
- HUMA 0.00
- Stochastic Oscillator
- DHY 50.00
- HUMA 9.26
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.